HOUSTON, Oct. 21, 2016 /PRNewswire/ -- NX Prenatal Inc. (NXPN), a privately held biotechnology company developing novel diagnostic tests in the women's health field, today announced the appointment of Kevin P. Rosenblatt, M.D., Ph.D., as Chief Medical Officer and Chief Scientific Officer. In this role, Dr. Rosenblatt will bring his extensive experience in biomarker discovery, clinical proteomics, and clinical assay development to advance NXPN's proprietary pipeline of exosome-based diagnostic tests.  He will be responsible for the strategy and execution of NXPN's first-in-class programs to exploit the biological and biophysical characteristics of exosomes for early identification of patients at risk of outcomes such as preterm birth.

"Dr. Rosenblatt is a proven clinical development executive with a track record of success in developing innovative tests and taking them through regulatory approval and market adoption," said Gail S. Page, executive chairman of NXPN. "His scientific and clinical background together with considerable expertise in the development of novel diagnostics will be a significant asset as we work to commercialize our breakthrough technology and support healthy pregnancy outcomes."

Dr. Rosenblatt has more than 26 years of clinical and biomedical research and development experience in multiple settings, including academia, biotech, startups, and clinical practice. Prior to joining NXPN, he was Chief Scientific Officer, Chief Medical Officer, and Clinical Laboratory Director at CompanionDx's CLIA/CAP certified reference lab. Among other appointments, he has served as Director of the Center for Clinical Proteomics at the Brown Foundation Institute of Molecular Medicine, as well as the Director of the UT Health Science Center at Houston's Center for Clinical and Translational Sciences Proteomics Core. Dr. Rosenblatt also serves as Associate Professor in the Division of Oncology, Department of Internal Medicine at UT Health and the McGovern Medical School and Associate Adjunct Professor in the School of Health Professions at the MD Anderson Cancer Center, both in Houston. Earlier in his career, Dr. Rosenblatt was co-founder and Laboratory Director of Risk Assessment Laboratories, which partnered with Perkin-Elmer to develop adverse pregnancy outcome biomarkers.

Dr. Rosenblatt received his M.D. and Ph.D. degrees from University of Texas Southwestern Medical School in Dallas. He completed his residency in anatomic pathology at the National Cancer Institute, followed by a clinical and research fellowship at NCI in translational pathology and tissue proteomics.

About NX Prenatal:

NX Prenatal Inc. is a private US based molecular diagnostics company developing assays for adverse pregnancy outcomes and conditions such as preterm birth. NX Prenatal's proprietary NeXosome® platform enables the rapid isolation and enrichment of exosome and microvesicle particles from maternal blood. These particles have been shown to be shed from the maternal and fetal tissues to help maintain a balance in certain immunologic and inflammatory processes that are common to successful pregnancy outcomes. The biomarker content of these exosome particles can reflect early signs of dysfunction and dysregulation in those processes, which can lead to adverse outcomes. The company has unlocked a new library of biomarkers for prenatal risk assessment for use as early as 10 weeks gestation. For more information, please visit the company's website at www.nxprenatal.com.

Photo - http://photos.prnewswire.com/prnh/20161021/431254
Logo - http://photos.prnewswire.com/prnh/20150526/218631LOGO

SOURCE NX Prenatal Inc.

Related Links

http://www.nxprenatal.com